Gain Therapeutics, Inc. (GANX)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating profit | $m | -19 | -19 | ||||||
| Net profit | $m | -4 | -14 | -18 | -22 | -20 | -20 | -20 | -16 |
| EPS reported | $ | -0.61 | -0.50 | ||||||
| Operating cashflow per share | $ | -0.56 | -0.44 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | -0.56 | -0.44 | ||||||
| Free cash flow | $m | -18 | -19 | ||||||
| Net debt | $m | -20 | -13 | ||||||
| Book value equity | $m | 19 | 11 | ||||||
| Book value per share | $ | 0.56 | 0.26 | ||||||
| Number of shares | m | 32.97 | 42.88 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 5.72 | 9.40 | ||||||
| P/S LTM | x | 0.00 | 0.00 | ||||||
| P/FCF LTM | x | -5.75 | -5.60 | ||||||
| EV/EBITDA LTM | x | -4.48 | -4.51 | ||||||
| EV/Sales LTM | x | 0.00 | 0.00 | ||||||
| Earnings Yield LTM | % | -18.99% | -22.12% | ||||||
| FCF Yield | % | -17.39% | -17.85% | ||||||
| Quality | |||||||||
| ROE | % | -108.60% | -161.58% | ||||||
| ROIC | % | -95.04% | -1.58% | ||||||
| Operating margin | % | 0.00% | 0.00% | ||||||
| Gross margin | % | 0.00% | 0.00% | ||||||
| FCF/Sales | % | - | - | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | - | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -25.22 | -31.08 | ||||||
| Net Debt/EBITDA | x | 1.05 | 0.67 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | +0.38% | +0.36% | ||||||
| Net debt/Equity | x | -1.10 | -1.13 | ||||||
| Gross debt/equity | x | 0.04 | 0.05 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Gain Therapeutics, Inc. is a biotechnology firm specializing in the creation of advanced treatments for conditions originating from improperly folded proteins. The company primarily directs its efforts towards rare genetic disorders and neurological ailments. It employs its unique Site-Directed Enzyme Enhancement Therapy (SEE-Tx) platform to pinpoint specific allosteric sites on malformed proteins. Subsequently, Gain Therapeutics identifies proprietary small molecules designed to bind to these locations, thereby restoring correct protein conformation and alleviating the disease. Their current development pipeline includes several structurally targeted allosteric regulator candidates aimed at combating a range of diseases, such as Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1. Established in 2017, the company is headquartered in Bethesda, Maryland.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Gain Therapeutics, Inc. is a biotechnology firm specializing in the creation of advanced treatments for conditions originating from improperly folded proteins. The company primarily directs its efforts towards rare genetic disorders and neurological ailments. It employs its unique Site-Directed Enzyme Enhancement Therapy (SEE-Tx) platform to pinpoint specific allosteric sites on malformed proteins. Subsequently, Gain Therapeutics identifies proprietary small molecules designed to bind to these locations, thereby restoring correct protein conformation and alleviating the disease. Their current development pipeline includes several structurally targeted allosteric regulator candidates aimed at combating a range of diseases, such as Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1. Established in 2017, the company is headquartered in Bethesda, Maryland.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free